What patients really want to know when managing their medication

2. Sep 2026 | B2B

Between the doctor’s consultation and everyday treatment “I would have liked more information about my medication” Patient organizations, healthcare researchers, and healthcare institutions have been receiving this feedback for years. This does not mean that there is...

Between promise and responsibility: What makes a good health app

5. Aug 2026 | B2B

Quality criteria between evidence, data quality, and sustainable patient access Health apps have long been part of strategic initiatives in pharmaceutical companies. Today, the question is no longer whether they are used, but which applications actually provide robust...

Direct-To-Patient (d2p) in the Pharmaceutical Industry: Between Regulatory Boundaries and Strategic Necessity

1. Jul 2026 | B2B, B2B_Patient_Engagement

How can pharmaceutical companies reach patients directly without taking regulatory risks or losing relevance? This question shapes the current discussion around direct-to-patient approaches. While direct patient communication has been established in the USA for...

Guidelines and Real-World Care: Why Evidence-Based Lipid Therapy Often Fails in Everyday Practice

3. Jun 2026 | B2B_Patient_Engagement

Cardiovascular guidelines are considered the gold standard of evidence-based medicine. The recommendations of the European Society of Cardiology and the European Atherosclerosis Society for lowering LDL cholesterol are clear, differentiated by risk profiles, and...

Gamification in medical knowledge communication: Opportunities for pharma and digital health?

6. May 2026 | B2B, B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD

How can complex medical knowledge be communicated in a way that is not only understood, but also applied in everyday life? This question concerns pharmaceutical companies as well as medical affairs teams and providers of digital health solutions. According to the...

From phase III to real-world care: why the patient perspective matters

1. Apr 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD

Randomized phase III trials are the gold standard of evidence-based drug development. They provide robust data on efficacy and safety and form the basis for regulatory decisions. However, with market approval, a new phase of evidence generation begins: the real-world...